The B-word is back, and it rhymes with "trouble." With 21 US IPOs in April alone, no wonder the barbarians are lined up at the ga...

Will the recent IPOs of Pacific Biosciences, a cut-rate Aegerion Pharmaceuticals, and a reportedly massive debut by a Chinese drug maker w...

Did you hear the one about two VCs, two fund managers, and a banker who walk into a bar… or maybe onto a stage. No, wait, it gets better. T...

FOTF never really goes on summer vacation, unlike those namby-pambies over at DOTW . But as befits the Most Interesting Biopharma Column in ...